Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

POM Wonderful Says Interviews Fall Outside FTC Advertising Scope

This article was originally published in The Pink Sheet Daily

Executive Summary

Claims about the benefits of pomegranate made in unpaid-for media appearances should not qualify as “advertising” under the FTC Act, argues POM Wonderful. Among the claims FTC is pursuing, POM owner Lynda Resnick told Newsweek that pomegranate juice is “40 percent as effective as Viagra.”

You may also be interested in...



Social Media Marketing Guidance Available In Existing Regs, Experts Say

Firms waiting for FDA to issue guidance on how best to use social media for marketing and promotion can look instead at existing regulations both in and outside the agency, experts said recently.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel